We have engineered a fusion between obinutuzumab and our Brainshuttle module (Brainshuttle‐CD20) to further enhance the potential clinical efficacy in the MS population by maximizing brain penetration. The gene discussed is MS4A1; the disease is myeloid sarcoma.